ENDRA Regains Nasdaq Compliance, Faces Year-Long Monitoring
NDRA sits 60% above its 52-week low of $2.96.
Summary
ENDRA Life Sciences has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving a critical delisting threat that emerged in April and was confirmed in May. This positive development likely stems from the company's recent definitive merger agreement with Noble Africa and associated financing. While the immediate delisting risk is removed, Nasdaq will subject ENDRA to a one-year discretionary monitoring period. During this time, any further non-compliance could lead to immediate delisting without a cure period, introducing a new, elevated risk for the company.
At the time of this announcement, NDRA was trading at $4.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $2.96 to $11.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.